A global equity firm well-versed in pharmaceutical investing is betting the ongoing frenzy in weight-loss drug stock has further to run.
Novo Nordisk and Eli Lilly are among top holdings in the A$1.3 billion Capital Group New Perspective Fund, which is beating 94 per cent of peers this year, according to data compiled by Bloomberg. The long-standing fund, which first invested in the two companies long before recent fervour for obesity treatments, claims ...
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: